Orchestra BioMed (NASDAQ:OBIO) Insider Purchases $18,850.00 in Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) insider David Hochman acquired 5,000 shares of Orchestra BioMed stock in a transaction on Friday, May 15th. The shares were bought at an average price of $3.77 per share, with a total value of $18,850.00. Following the purchase, the insider directly owned 1,059,029 shares in the company, valued at approximately $3,992,539.33. The trade was a 0.47% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Orchestra BioMed Stock Performance

NASDAQ OBIO opened at $4.10 on Friday. The stock has a 50-day simple moving average of $4.25 and a two-hundred day simple moving average of $4.27. The firm has a market capitalization of $245.51 million, a P/E ratio of -4.23 and a beta of 0.52. Orchestra BioMed Holdings, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $5.42. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.01 and a current ratio of 7.03.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.07. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.92 million. On average, equities analysts forecast that Orchestra BioMed Holdings, Inc. will post -1.47 earnings per share for the current year.

Institutional Investors Weigh In On Orchestra BioMed

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Orchestra BioMed by 28.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock worth $3,675,000 after buying an additional 324,558 shares in the last quarter. Alyeska Investment Group L.P. purchased a new stake in Orchestra BioMed during the 3rd quarter worth approximately $3,386,000. Pathstone Holdings LLC purchased a new stake in Orchestra BioMed during the 3rd quarter worth approximately $2,495,000. Geode Capital Management LLC increased its stake in Orchestra BioMed by 22.4% during the 4th quarter. Geode Capital Management LLC now owns 473,363 shares of the company’s stock worth $1,965,000 after buying an additional 86,564 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Orchestra BioMed by 46.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 263,788 shares of the company’s stock worth $1,095,000 after buying an additional 83,349 shares in the last quarter. 53.20% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Barclays lifted their price target on Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Wall Street Zen lowered Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Orchestra BioMed in a research note on Thursday, May 14th. Chardan Capital restated a “buy” rating and issued a $20.00 price target on shares of Orchestra BioMed in a research note on Thursday, March 12th. Finally, Weiss Ratings lowered Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Orchestra BioMed currently has a consensus rating of “Moderate Buy” and an average price target of $13.60.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.